Year Founded
2008
Ownership
Private
Employees
~50
Stage
Phase 2
Modalities
Small molecule

Intrepid Therapeutics General Information

Lead compound emricasan has been studied in over 500 subjects across 10 clinical trials, showing statistically significant reductions in ALT and cCK18 biomarkers. Planning Phase 2b ACLF trial, Phase 2b/3 HCV-POLT trial, and Phase 2b CLF trial.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

emricasan
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Intrepid Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Intrepid Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Intrepid Therapeutics's complete valuation and funding history, request access »